热门资讯> 正文

Hefei BioPharma Corp. GAAP每股收益为C$-0.01

2026-03-18 00:06

HELIX ACQUISITION CORP.(HLXA) 0

Helix BioPharma Corp. press release (HBP:CA): Q2 GAAP EPS of C$-0.01.
Reported a net and total comprehensive loss from operations of C$0.7M in Q2 2026.
The Company had cash of C$0.03M as of January 31, 2026, down from C$2M at the end of the three months ended January 31, 2025.

More on Helix BioPharma Corp.

Financial information for Helix BioPharma Corp.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。